230 related articles for article (PubMed ID: 11595720)
1. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu expression in malignant lung tumors.
Hirsch FR; Franklin WA; Veve R; Varella-Garcia M; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):51-8. PubMed ID: 11894014
[TBL] [Abstract][Full Text] [Related]
5. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
6. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
[TBL] [Abstract][Full Text] [Related]
11. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer.
Cox G; Vyberg M; Melgaard B; Askaa J; Oster A; O'Byrne KJ
Int J Cancer; 2001 May; 92(4):480-3. PubMed ID: 11304680
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
Hirsch FR; Varella-Garcia M; Franklin WA; Veve R; Chen L; Helfrich B; Zeng C; Baron A; Bunn PA
Br J Cancer; 2002 May; 86(9):1449-56. PubMed ID: 11986780
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
14. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.
Tsai CM; Chang KT; Perng RP; Mitsudomi T; Chen MH; Kadoyama C; Gazdar AF
J Natl Cancer Inst; 1993 Jun; 85(11):897-901. PubMed ID: 8098377
[TBL] [Abstract][Full Text] [Related]
15. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
17. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
Morabito A; Longo R; Gattuso D; Carillio G; Massaccesi C; Mariani L; Bonginelli P; Amici S; De Sio L; Fanelli M; Torino F; Bonsignori M; Gasparini G
Oncol Rep; 2006 Aug; 16(2):393-8. PubMed ID: 16820921
[TBL] [Abstract][Full Text] [Related]
19. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Hussain MH; MacVicar GR; Petrylak DP; Dunn RL; Vaishampayan U; Lara PN; Chatta GS; Nanus DM; Glode LM; Trump DL; Chen H; Smith DC;
J Clin Oncol; 2007 Jun; 25(16):2218-24. PubMed ID: 17538166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
